Bionano Genomics (NASDAQ: BNGO) stock surged 9.83% in pre-market trading on Tuesday, following the announcement of a groundbreaking study published in The Journal of Molecular Diagnostics. The study describes an innovative method for analyzing multiple myeloma (MM) using Bionano's optical genome mapping (OGM) technology.

The research, conducted at Lille University Hospital in France, overcomes a significant hurdle in MM analysis by demonstrating that mixing CD138-positive with CD138-negative cells at a 1:1 ratio is sufficient for OGM analysis. This breakthrough effectively halves the number of CD138-positive cells required, addressing the challenge of limited sample quantities in MM research.

Investors appear enthused by the study's key findings, which highlight OGM's potential to revolutionize MM analysis. The technology showed 93% concordance with current standard FISH testing while uncovering 22 additional genetic variants. Moreover, OGM's ability to consolidate multiple assessments into a single, comprehensive approach could streamline laboratory workflows and improve prognostic risk evaluation for MM patients.

Erik Holmlin, CEO of Bionano Genomics, emphasized the significance of this publication, stating it "marks an important advancement for OGM research in hematologic malignancies." The company believes this development could expand the adoption of OGM in routine clinical use, particularly for multiple myeloma, which represents a significant unmet medical need in the field of blood cancers.